Vivani Medical
Open
$1.34
Prev. Close
$1.34
High
$1.35
Low
$1.34
Market Snapshot
$96.3M
-3.6
-0.44
42
Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. The company is headquartered in Alameda, California and currently employs 42 full-time employees. The company went IPO on 2014-12-05. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.
emptyResult
Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. The company is headquartered in Alameda, California and currently employs 42 full-time employees. The company went IPO on 2014-12-05. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.
Recently from Cashu
Vivani Medical: Thriving Amid Economic Uncertainty in Medical Technology
Navigating Economic Uncertainty in the Medical Technology Sector Vivani Medical, a pioneering company in the field of implantable drug delivery systems, stands at a pivotal juncture amid the current e…
Vivani Medical: Navigating Economic Uncertainty with Innovative Drug Delivery Solutions
Navigating Economic Uncertainty: Insights from American Century Investments In an evolving economic landscape, American Century Investments emphasizes the importance of patience and discipline for inv…
Vivani Medical: Thriving Amid Economic Uncertainty in Biotech Innovation
Navigating Economic Uncertainty: Insights for Biotech Innovation Vivani Medical, a prominent player in the biotechnology industry, operates in an environment marked by rapid innovation and growing eco…
Vivani Medical Addresses Visual Health Crisis in Children from Excessive Screen Time
Raising Awareness: The Visual Health Crisis Among Children Due to Excessive Screen Time Dr. Bryce Appelbaum, a board-certified optometrist, highlights a growing concern regarding the excessive screen…